Table S5 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma

Table S5 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma

<p>List of recurrent mutations with potential utility as neoantigens</p>

Shranjeno v:

Bibliografske podrobnosti
Glavni avtor:	Lijun Yao (15292963) (author)
Drugi avtorji:	Julia T. Wang (15292966) (author), Reyka G. Jayasinghe (15131798) (author), Julie O'Neal (15292969) (author), Chia-Feng Tsai (15292972) (author), Michael P. Rettig (15292975) (author), Yizhe Song (15292978) (author), Ruiyang Liu (15292981) (author), Yanyan Zhao (15292984) (author), Omar M. Ibrahim (15292987) (author), Mark A. Fiala (15032471) (author), Julie M. Fortier (15292990) (author), Siqi Chen (15292993) (author), Leah Gehrs (15292996) (author), Fernanda Martins Rodrigues (15292999) (author), Michael C. Wendl (15293002) (author), Daniel Kohnen (15293005) (author), Andrew Shinkle (15293008) (author), Song Cao (15293011) (author), Steven M. Foltz (15293014) (author), Daniel Cui Zhou (15293017) (author), Erik Storrs (15293020) (author), Matthew A. Wyczalkowski (15293023) (author), Smrithi Mani (15293026) (author), Scott R. Goldsmith (15293029) (author), Ying Zhu (15293032) (author), Mark Hamilton (15131831) (author), Tao Liu (15293035) (author), Feng Chen (15293038) (author), Ravi Vij (15293041) (author), Li Ding (15061726) (author), John F. DiPersio (15293044) (author)
Izdano:	2025
Teme:	Cancer Immuno-oncology Methods and Technology Hematological Cancers Myelomas Immunotherapy Single Cell Technologies
Oznake:	Označite Brez oznak, prvi označite!

Podobne knjige/članki

Table S1 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
od: Lijun Yao (15292963)
Izdano: (2025)

Table S2 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
od: Lijun Yao (15292963)
Izdano: (2025)

Table S3 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
od: Lijun Yao (15292963)
Izdano: (2025)

Table S4 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
od: Lijun Yao (15292963)
Izdano: (2025)

Table S6 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
od: Lijun Yao (15292963)
Izdano: (2025)

Supplementary Spreadsheet S5 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
od: Eileen M. Boyle (15015425)
Izdano: (2025)

Supplementary Spreadsheet S1 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
od: Eileen M. Boyle (15015425)
Izdano: (2025)

Supplementary Spreadsheet S10 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
od: Eileen M. Boyle (15015425)
Izdano: (2025)

Supplementary Spreadsheet S11 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
od: Eileen M. Boyle (15015425)
Izdano: (2025)

Supplementary Spreadsheet S12 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
od: Eileen M. Boyle (15015425)
Izdano: (2025)

Supplementary Spreadsheet S2 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
od: Eileen M. Boyle (15015425)
Izdano: (2025)

Supplementary Spreadsheet S3 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
od: Eileen M. Boyle (15015425)
Izdano: (2025)

Supplementary Spreadsheet S4 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
od: Eileen M. Boyle (15015425)
Izdano: (2025)

Supplementary Spreadsheet S6 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
od: Eileen M. Boyle (15015425)
Izdano: (2025)

Supplementary Spreadsheet S7 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
od: Eileen M. Boyle (15015425)
Izdano: (2025)

Supplementary Spreadsheet S8 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
od: Eileen M. Boyle (15015425)
Izdano: (2025)

Supplementary Spreadsheet S9 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
od: Eileen M. Boyle (15015425)
Izdano: (2025)

Supplementary Data S1 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
od: Keiji Kurata (15055090)
Izdano: (2025)

Supplementary Data S2 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
od: Keiji Kurata (15055090)
Izdano: (2025)

Supplementary Data S3 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
od: Keiji Kurata (15055090)
Izdano: (2025)

Supplementary Table 5 from Super Enhancer-Mediated Upregulation of <i>HJURP</i> Promotes Growth and Survival of t(4;14)-Positive Multiple Myeloma
od: Yunlu Jia (2012017)
Izdano: (2025)

Supplementary Table 1 from Super Enhancer-Mediated Upregulation of <i>HJURP</i> Promotes Growth and Survival of t(4;14)-Positive Multiple Myeloma
od: Yunlu Jia (2012017)
Izdano: (2025)

Supplementary Table 2 from Super Enhancer-Mediated Upregulation of <i>HJURP</i> Promotes Growth and Survival of t(4;14)-Positive Multiple Myeloma
od: Yunlu Jia (2012017)
Izdano: (2025)

Supplementary Table 3 from Super Enhancer-Mediated Upregulation of <i>HJURP</i> Promotes Growth and Survival of t(4;14)-Positive Multiple Myeloma
od: Yunlu Jia (2012017)
Izdano: (2025)

Supplementary table 5 from Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy
od: Wei Chen (15053713)
Izdano: (2025)

Supplementary table 6 from Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy
od: Wei Chen (15053713)
Izdano: (2025)

Supplementary table 7 from Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy
od: Wei Chen (15053713)
Izdano: (2025)

Discovery and Characterization of Novel BLIMP‑1 Heterobifunctional Ligand-Directed Degraders
od: Bryan J. Simmons (22676881)
Izdano: (2025)

Supplementary Data from NKG7 Is a T-cell–Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy
od: Ti Wen (15130158)
Izdano: (2025)

Correlation between duration of first-line treatment with daratumumab, lenalidomide, and dexamethasone and overall survival in patients with transplant-ineligible multiple myeloma in Japan
od: Kazuhito Suzuki (22688384)
Izdano: (2025)

Supplementary Table S1 from Integrative Single-Cell and Bulk Transcriptomes Analyses Identify Intrinsic HNSCC Subtypes with Distinct Prognoses and Therapeutic Vulnerabilities
od: Yibin Dai (16374331)
Izdano: (2025)

Supplementary Table S2 from Integrative Single-Cell and Bulk Transcriptomes Analyses Identify Intrinsic HNSCC Subtypes with Distinct Prognoses and Therapeutic Vulnerabilities
od: Yibin Dai (16374331)
Izdano: (2025)

Table S5 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
od: Stéphane Fattori (15048281)
Izdano: (2025)

Supplementary Tables S1-S11 from Adult Low-Hypodiploid Acute Lymphoblastic Leukemia Emerges from Preleukemic <i>TP53</i>-Mutant Clonal Hematopoiesis
od: Rathana Kim (15135915)
Izdano: (2025)

File_S1 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
od: Stéphane Fattori (15048281)
Izdano: (2025)

Table S1 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
od: Stéphane Fattori (15048281)
Izdano: (2025)

Table S2 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
od: Stéphane Fattori (15048281)
Izdano: (2025)

Table S3 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
od: Stéphane Fattori (15048281)
Izdano: (2025)

Table S4 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
od: Stéphane Fattori (15048281)
Izdano: (2025)

Table S6 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
od: Stéphane Fattori (15048281)
Izdano: (2025)

Cannot write session to /tmp/vufind_sessions/sess_6e6nuj4el1969mmb76tfeajfts